vs
Side-by-side financial comparison of Grace Therapeutics, Inc. (GRCE) and Inventiva S.A. (IVA). Click either name above to swap in a different company.
Delix Therapeutics is an American biotech company based in Boston, Massachusetts. The company develops novel neuroplasticity-promoting therapeutics for central nervous system (CNS) diseases such as depression and post-traumatic stress disorder (PTSD). It was co-founded in 2019 by David E. Olson and Nick Haft.
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients living with fibrosis, rare diseases, and oncological conditions. It advances a pipeline of targeted product candidates, with key operations across Europe and North America, serving patient populations with high unmet medical needs worldwide.
GRCE vs IVA — Head-to-Head
Income Statement — Q3 FY2022 vs Q2 FY2024
| Metric | | |
|---|---|---|
| Revenue | $0 | $5.1K |
| Net Profit | $-3.8M | $-49.0M |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | — | -961352.9% |
| Revenue YoY | — | — |
| Net Profit YoY | -17.3% | — |
| EPS (diluted) | $-0.09 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $46.3M | $11.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $111.1M | $-85.4M |
| Total Assets | $114.2M | $42.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 24 | — | $11.0M | ||
| Q4 21 | $46.3M | — |
| Q2 24 | — | $-85.4M | ||
| Q4 21 | $111.1M | — |
| Q2 24 | — | $42.6M | ||
| Q4 21 | $114.2M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.6M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 24 | — | — | ||
| Q4 21 | $-4.6M | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
